Artan Bio's lead drug candidate just took a major step towards clinical reality for $VITARNA New drop from the frontlines of aging science: 🧵👇

Following their Synex partnership to fast-track delivery of ARTAN-102, Artan Bio has now entered clinical trial discussions with regulators in Abu Dhabi. The next milestone: first-in-human (FIH) validation.

ARTAN-102 is designed to restore the body’s ability to repair itself by fixing nonsense mutations that disrupt key cellular functions in aging. If approved, this would mark the first clinical test of codon suppression in humans.

What's happening now: - Regulators meetings held - Use case discussed - Trial scope articulated Foundational steps, carefully underway.

This is what early-stage translation looks like. From codon-level science to clinical momentum. You can track the underlying IP here: